Related Experiment Video
Updated: Jun 12, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Sample size for post-marketing safety studies based on historical controls.
1Division of Biometrics VII, Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. yutewu@yahoo.com
Pharmacoepidemiology and Drug Safety
|June 24, 2010
Summary
A new hybrid study design using historical data requires fewer participants for post-marketing drug safety surveillance. This method improves efficiency in identifying rare adverse events compared to traditional prospective studies.
Area of Science:
- Pharmacovigilance and Drug Safety
- Biostatistics
- Clinical Trial Design
Background:
- Post-marketing studies are crucial for identifying rare, serious adverse events in drug lifecycles.
- Regulatory bodies like the US Food and Drug Administration (FDA) are emphasizing enhanced safety monitoring.
- Traditional two-group prospective cohort studies are resource-intensive for detecting infrequent events.
Purpose of the Study:
- To develop an exact sample size formula for a novel hybrid post-marketing study design.
- To incorporate historical external data into a two-group cohort study framework.
- To provide a statistically rigorous method for sample size calculation in safety surveillance.
Main Methods:
- Development of an exact sample size formula utilizing the Poisson distribution.
- Focus on the detection of rare events as the primary outcome.
- Comparison of the exact method's performance against its approximate large-sample theory counterpart.
Main Results:
- The proposed hybrid design demonstrates a reduced sample size requirement compared to standard two-group prospective studies.
- The exact sample size method offers a significant reduction, up to 30%, in the number of subjects needed in the treatment group versus the approximate method.
- Efficiency gains are particularly notable for the study scenarios evaluated.
Conclusions:
- The hybrid study design effectively combines the benefits of two-group studies with improved sample size efficiency.
- This approach offers a practical and statistically sound solution for post-marketing safety studies.
- The findings support the adoption of this hybrid design for more resource-conscious drug safety surveillance.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...